Drug Discovery News: Silence in healthy cells makes FOXR2 a potential cancer target
Drug Discovery News recently highlighted research coauthored by the University of Cincinnati's Timothy Phoenix, PhD, focused on a gene called FOXR2.
FOXR2 is usually not expressed in most healthy cells, but the research team found it is abnormally expressed in more than 70% of 10,000 different adult and pediatric cancer types the team analyzed
The research team also found that FOXR2 bound to the DNA sequences that normally associate with E26 transformation-specific (ETS) transcription factors (ETS TFs), which control the expression of genes with a variety of cellular functions.
“FOXR2 and ETS TFs can interact on DNA and actually turn genes on and off, which can cause cancer,” said Phoenix, assistant professor in UC’s James L. Winkle College of Pharmacy Division of Pharmaceutical Sciences and a University of Cincinnati Cancer Center researcher.
Moving forward, the team aims to learn more about exactly how FOXR2 functions and the proteins it interacts with, with long-term goals of developing targets for new treatments.
Read the Drug Discovery News story.
Featured photo at top of Phoenix in his lab. Photo/Colleen Kelley/UC Marketing + Brand
Related Stories
Drug Discovery News: Silence in healthy cells makes FOXR2 a potential cancer target
April 7, 2023
Drug Discovery News highlighted research coauthored by the University of Cincinnati's Timothy Phoenix that found a gene called FOXR2 is abnormally expressed in more than 70% of cancer types sampled and could be a potential target for new treatments.
Physics World: Engineered bacteria attract cancer-killing radioisotopes into tumors
April 14, 2023
Physics World highlighted research led by the University of Cincinnati's Nalinikanth Kotagiri that shows a proof of concept for using engineered bacteria as an adapter to deliver targeted radionuclide treatment to tumors.
The Oncology Nursing Podcast: UC expert discusses antimetabolite drugs
December 4, 2023
The University of Cincinnati's Rowena Schwartz joined The Oncology Nursing Podcast to discuss what oncology nurses need to know about a class of drugs called antimetabolites.
MedPage Today: Promising results for living donor transplants
April 5, 2022
The University of Cincinnati's Shimul Shah, MD, was featured in a MedPage Today article highlighting recent research on the success of living donor transplants for patients with unresectable colorectal cancer liver metastases.
Yahoo! News: Electricity cap used to treat brain tumors
April 18, 2022
Yahoo! News featured University of Cincinnati research into the use of Optune devices that provide electrical field treatment to the brain as a treatment for glioblastomas.
Healio: Immunotherapy does not increase surgery complications for oral cavity cancer patients
May 2, 2022
The University of Cincinnati's Alice Tang was featured in a Healio article discussing recently published research that administering an immunotherapy drug prior to surgery did not increase risks for patients with advanced oral cavity cancer.
Imaging Technology News: First FLASH proton therapy trial completed in humans
May 27, 2022
The University of Cincinnati's John Breneman, MD, spoke with Imaging Technology News about the completion of enrollment of the FAST-01 trial, the first FLASH proton therapy trial completed in humans.
OncLive: ADCs emerge as exciting addition to ovarian cancer treatment
January 3, 2023
The University of Cincinnati's Caroline Billingsley, MD, was featured in a Q&A article on OncLive discussing the use of antibody-drug conjugates in ovarian cancer treatment.
Wall Street Journal: More young people are getting colorectal cancers
March 2, 2023
The University of Cincinnati's Jordan Kharofa provided comments to the Wall Street Journal on a recent study that found a larger share of colorectal cancer patients are being diagnosed at a younger age and at a more dangerous stage of the disease.
Medical News Today: Gene mutation may be a key to lung cancer treatment
September 21, 2022
Medical News Today highlighted recent research led by the University of Cincinnati's Pier Paolo Scaglioni, MD, that found targeting components of lipid metabolism and synthesis could lead to an effective lung cancer treatment.